Invention Grant
- Patent Title: Compounds useful as kinase inhibitors
-
Application No.: US16063542Application Date: 2016-12-16
-
Publication No.: US10695323B2Publication Date: 2020-06-30
- Inventor: Nicolas Guisot
- Applicant: Loxo Oncology, Inc.
- Applicant Address: US CT Stamford
- Assignee: Loxo Oncology, Inc.
- Current Assignee: Loxo Oncology, Inc.
- Current Assignee Address: US CT Stamford
- Agent Tina M Tyson; James B Myers
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@5d27a1a4 com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@36e79f51
- International Application: PCT/GB2016/053968 WO 20161216
- International Announcement: WO2017/103611 WO 20170622
- Main IPC: C07D231/38
- IPC: C07D231/38 ; C07D401/04 ; C07D401/06 ; C07D403/04 ; C07D405/04 ; C07D405/08 ; C07D405/14 ; C07D413/06 ; C07D417/04 ; A61P35/02 ; A61P37/02 ; A61K31/415 ; C07D231/14 ; A61K45/06 ; C07D405/06 ; A61P35/00 ; A61K31/4155
Abstract:
This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
Public/Granted literature
- US20190135762A1 COMPOUNDS USEFUL AS KINASE INHIBITORS Public/Granted day:2019-05-09
Information query
